益生菌在炎症性肠病中新兴的治疗作用。
The emerging therapeutic role of probiotics in inflammatory bowel disease.
作者信息
Chandler Matthew, Wollins Eric, Toles Anastasia, Borum Marie, Doman David B
机构信息
Dr. Doman serves as Clinical Professor of Medicine at George Washington University School of Medicine in Washington, DC, where Drs. Chandler and Wollins are Fellows in Gastroenterology. Dr. Toles is also affiliated with George Washington University of Medicine, as is Dr. Borum, who serves as the Chief of the Division of Gastroenterology and Professor of Medicine.
出版信息
Gastroenterol Hepatol (N Y). 2008 Sep;4(9):634-40.
Nonpathogenic bacteria in a genetically susceptible individual play a suggestive role in the pathogenesis of inflammatory bowel disease (IBD). Probiotics are living organisms that exert a protective effect on intestinal mucosa. Although evidence supporting their use for inducing or maintaining remission of IBD remains limited, it may be reasonable to use probiotics as an adjunct to standard therapy for mild-to-moderate disease. Genetically modified probiotics may provide novel delivery methods of therapeutic payloads to inflamed intestinal mucosa. This review focuses on the emerging use of probiotics in the treatment of IBD.
在基因易感性个体中，非致病性细菌在炎症性肠病（IBD）的发病机制中起提示作用。益生菌是对肠道黏膜具有保护作用的活生物体。尽管支持其用于诱导或维持IBD缓解的证据仍然有限，但将益生菌用作轻至中度疾病标准治疗的辅助手段可能是合理的。基因工程益生菌可能为将治疗性有效载荷递送至炎症性肠黏膜提供新的方法。本综述重点关注益生菌在IBD治疗中的新用途。
Zotero 插件